Immunohistochemical studies of vascular endothelial growth factor in skin of patients with amyotrophic lateral sclerosis

Journal of the Neurological Sciences

Volumn 285, Issue 1-2, 2009, Pages 125-129

  Suzuki, Megumi ^a   Watanabe, Takeshi ^a   Mikami, Hirotsugu ^a   Nomura, Makoto ^a   Yamazaki, Toshihiro ^a   Irie, Togo ^a   Yasui, Hiroaki Ishikawa Kanako ^a   Ono, Seiitsu ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Epidermis; Immunohistochemistry; Motor neuron; Skin; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELASTIC FIBER; EPIDERMIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN BIOPSY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD VESSELS; DERMIS; DISEASE PROGRESSION; EPIDERMIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; SKIN; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69549105802     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.06.021     Document Type: Article

References (34)

1. Ono S., Toyokora Y., Mannen T., and Ishibashi Y. Amyotrophic lateral sclerosis: histological, histochemical, and ultrastructural abnormalities of skin. Neurology 36 (1986) 948-956
2. Ono S., and Yamauchi M. Elastin cross-linking in the skin from patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 57 (1994) 94-96
3. Ono S., Imai T., Aso A., Yamano T., and Shimizu N. Alterations of skin glycosaminoglycans in patients with ALS. Neurology 51 (1998) 399-404
4. Furukawa T., and Toyokura Y. Amyotrophic lateral sclerosis and bedsores. Lancet 1 (1976) 862
5. Uebayashi Y., Yase Y., Tanaka H., Shimada Y., and Toyokura Y. Prognosis of motor neuron disease in Japan. Neuroepidemiology 2 (1983) 243-256
6. Iijima K., Yoshikawa N., and Nakamura H. Activation-induced expression of vascular permeability factor by human peripheral T cells: a non-radioisotopic semiquantitative reverse transcription-polymerase chain reaction assay. J Immunol Methods 196 (1996) 199-209
7. Hayashi T., Ishida Y., Kimura A., Takayasu T., Eisenmenger W., and Kondo T. Forensic application of VEGF expression to skin wound age determination. Int J Legal Med 118 (2004) 320-325
8. Tsou R., Fathke C., Wilson L., Wallace K., Gibran N., and Isik F. Retroviral factor receptor type 2 to murine wounds inhibits wound angiogenesis. Wound Repair Regen 10 (2002) 222-229
9. Sondell M., Lundborg G., and Kanje M. The vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19 (1999) 5731-5740
10. Schratzberger P., Schatzberger G., Silver M., Curry C., Kearney M., Magner M., et al. Favourable effect of the vascular endothelial growth factor gene transfer on ischemic peripheral neuropathy. Nat Med 6 (2000) 405-413
11. Jin K., Zhu Y.H., Sun Y.J., Mao X.O., Xie L., and Greenberg D.A. The vascular endothelial growth factor stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99 (2002) 24311946-24311950
12. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., et al. VEGF is a modifiber of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 (2003) 383-394
13. Brooks B.R. El Escorial World Federation of Neurology criteria for amyotrophic lateral sclerosis. J Neurol Sci 124 (1994) 96-107
14. Mathoney F.I., and Barthel D.W. Functional evaluation: the Barthel index. Med J 14 (1965) 61-65
15. Hsu S.M., Raine L., and Fanger H. Use of avidin-biotin-peroxidase complete immunoperoxidase techniques; a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29 (1981) 577-580
16. Nissen N.N., Polverini P.J., Koch A.E., Volin M.V., Gamelli R.L., and DiPietro L.A. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152 (1998) 1445-1452
17. Brown L.F., Yeo K.T., Berse B., Yeo T.K., Senger D.R., Dvorak H.F., et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176 (1992) 1375-1379
18. Detmar M., Brown L.F., Claffey K.P., Yeo K.T., Kocher O., Jackman R.W., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180 (1994) 1141-1146
19. Weninger W., Uthman A., Pammer J., Pichier A., Ballaun C., Lang I.M., et al. Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest 75 (1996) 647-657
20. Larcher F., Robles A.I., Duran H., Murillas R., Quintanilla M., Cano A., et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56 (1996) 5391-5396
21. Brown L.F., Harrist T.J., Yeo K.T., Ståhle-Bäckdahl M., Jackman R.W., and Berse B. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol 104 (1995) 744-749
22. Raleigh J.A., Calkins-Adams D.P., Rinker L.H., Ballenger C.A., Weissler M.C., Fowler Jr. W.C., et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58 (1998) 3765-3768
23. Kishimoto J., Ehama R., Ge Y., Kobayashi T., Nishiyama T., Detmar M., et al. In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol 157 (2000) 103-110
24. Detmar M. The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 24 (2000) S78-S84
25. Detmar M., Brown L.F., Berse B., Jackman R.W., Elicker B.M., Dvorak H.F., et al. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 108 (1997) 263-268
26. Zheng C., Nennesmo I., Fadeel B., and Henter J.I. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 56 (2004) 564-567
27. Svensson B., Peters M., König H.G., Poppe M., Levkau B., Rothermundt M., et al. Vascular endothelial growth factor protects cultured rat hippocampal neurons against hypoxic injury via an antiexcitotoxic, caspase-independent mechanism. J Cereb Blood Flow Metab 22 (2002) 1170-1175
28. Haigh J.J., Morelli P.I., Gerhardt H., Haigh K., Tsien J., Damert A., et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol 262 (2003) 225-241
29. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
30. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 (2004) 413-417
31. Iłzecka J. Does VEGF represent a potential treatment for amyotrophic lateral sclerosis?. Curr Opin Investig Drugs 7 (2006) 54-59
32. Chen D., Shen L., Wang L., Lu A., Zhang H., Zhang X., et al. Association of polymorphisms in vascular endothelial growth factor gene with the age of onset of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 8 (2007) 144-149
33. Devos D., Moreau C., Lassalle P., Perez T., De Seze J., Brunaud-Danel V., et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 62 (2004) 2127-2129
34. Ilzecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 106 (2004) 289-293